International guidelines can help identify dermatomyositis patients with a particularly high risk for cancer, according to a retrospective single-center U.S. study.
Among 413 patients with a known dermatomyositis diagnosis, risk stratification using International Myositis Assessment and Clinical Studies Group (IMACS) guidelines showed that 8.8% of the group considered high risk had a paraneoplastic dermatomyositis, as did 5.1% of the intermediate-risk group and 2.5% of the low-risk group.
Overall, 6.5% of the study population had a paraneoplastic dermatomyositis, meaning a cancer in the 3 years before or after the onset of dermatomyositis, reported Saakshi Khattri, MD, of the Icahn School of Medicine at Mount Sinai in New York City, and colleagues in ACR Open Rheumatology.
The findings support the discriminatory ability of the IMACS risk stratification guidelines and suggest that intermediate-risk patients should receive continued monitoring as well, the researchers said.
Age and Risk Factors
Although two or more high-risk factors were not significantly associated with malignancy, age ≥40 years was significantly associated with paraneoplastic dermatomyositis [DM],
Fuente: https://www.medpagetoday.com/dermatology/generaldermatology/122155
Join the doctors who get the most relevant medical news, curated by specialty, every week — no spam, unsubscribe anytime.
